Teleflex Inc. Secures FDA Clearance for Expanded Use of QuikClot Control+ Device

April 30, 2025 — Teleflex Incorporated (NYSE: TFX), a global medical technology provider, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for an expanded indication of the QuikClot Control+ Hemostatic Device. This clearance allows the device to be used for all grades of internal and external bleeding, broadening its application in various medical procedures.

The expanded indication is expected to enhance the device’s utility in trauma, general surgery, gynecologic surgery, orthopedic surgery, and other areas where effective bleeding control is critical. The FDA’s decision was based on real-world evidence from a retrospective analysis, underscoring the device’s efficacy and safety in a broader range of clinical scenarios.

Conference Presentation at BofA Securities 2025 Health Care Conference

In addition to the FDA clearance, Teleflex’s management is set to present at the BofA Securities 2025 Health Care Conference. The presentation will take place on May 14, 2025, at 1:40 p.m. Pacific Time, at the Encore Hotel in Las Vegas, Nevada. A live audio webcast of the event will be available on the investor section of Teleflex’s website, providing an opportunity for investors and industry stakeholders to engage with the company’s leadership.

Company Overview

Teleflex Incorporated is a leading provider of medical technologies, focusing on the development, manufacturing, and supply of single-use medical devices essential for critical care and surgical applications. The company’s products are widely used by hospitals and healthcare providers for common diagnostic and therapeutic procedures.

Financial Overview

As of April 23, 2025, Teleflex’s stock closed at $135.66. The company’s market capitalization stands at approximately $6.06 billion USD. Over the past year, the stock has experienced a 52-week high of $249.91 on September 26, 2024, and a 52-week low of $124.66 on April 8, 2025. The price-to-earnings ratio is currently 94.44.

This news highlights Teleflex’s ongoing commitment to innovation and expanding the capabilities of its medical devices to meet the evolving needs of healthcare providers and patients.